CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
BNP (nesiritide) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00405548
NCT00405548Phase 2Completed
CompareCT.gov

To Define in Human Preclinical Diastolic Dysfunction (PDD) the Actions of Chronic Administration of Subcutaneous (SQ) BNP on the Left Ventricular, Renal and Humoral Function and on the Integrated Response to Acute Sodium Loading

Mayo Clinic·interventional·Posted Nov 30, 2006·Updated Jul 1, 2015

In Brief

A Phase 2 clinical trial evaluating BNP (nesiritide) and Placebo for Left Ventricular Diastolic Dysfunction. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The purpose of this research study is to evaluate the effects of cardiac hormone replacement with SQ (subcutaneous or under the skin) injection of BNP (brain natriuretic peptide, a hormone produced by the heart) on the pumping ability of the heart, kidney function and levels of different hormones in the blood in response to an intravenous salt solution.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeft Ventricular Diastolic Dysfunction
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Scios, Inc., National Heart, Lung, and Blood Institute (NHLBI), National Center for Research Resources (NCRR)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 30, 2006
Enrollment StartMar 1, 2008
Primary CompletionApr 1, 2011
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.6 years ago

Interventions

BNP (nesiritide)drug

Placebodrug